ADI-001 exhibited robust in vitro and in vivo tumor growth inhibition in multiple human lymphoma cell lines, with adaptive and innate mechanisms contributing to its anti-tumor activity
Non-gene-edited ADI-001 gamma delta CAR T cells demonstrated superior resilience to host versus graft targeting when compared to common gene-edited approaches
MENLO PARK, CA & BOSTON, MA, USA I May 05, 2022 I Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced data from a preclinical evaluation of ADI-001 at the International Society for Cell and Gene Therapy (ISCT) Annual Meeting taking place in San Francisco, May 4-7, 2022. ADI-001 is currently being evaluated in an ongoing dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin’s lymphoma (NHL).
The extensive preclinical evaluation reported at ISCT observed that ADI-001 exhibited a predominantly naïve-like T cell memory phenotype, expressed multiple chemokine and innate-activating cell receptors and exhibited robust in vitro and in vivo tumor growth inhibition against multiple human lymphoma cell lines, with adaptive and innate activation pathways contributing to the anti-tumor activity of ADI-001.
Susceptibility to host versus graft targeting was also evaluated using mixed-lymphocyte reactions incorporating up to 13 different allogeneic lymphocyte samples. Non-gene-edited ADI-001 gamma delta CAR T cells demonstrated high levels of endogenous HLA-E expression in the unmodified state and were associated with superior resilience to lymphocyte-mediated clearance when compared to approaches commonly deployed in gene-edited allogeneic cell therapy platforms (β2MKO with or without HLA-E overexpression).
“In this first view comparing Adicet’s non-gene-edited gamma delta CAR T cells to alternative and popularly-reported gene editing strategies, we appreciate the lower preclinical susceptibility to host versus graft targeting demonstrated by non-gene-edited ADI-001,” said Blake Aftab, Ph.D., Chief Scientific Officer at Adicet. “Together, the results of this extended characterization highlight potential advantages of our allogeneic gamma delta T cell platform, with adaptive and innate mechanisms contributing to the anti-tumor activity of ADI-001.”
Poster Presentation Details
Title: Evaluation of non-gene edited allogeneic “off-the-shelf” Vδ1 γδ (gamma delta) CAR T cells targeting CD20 for B cell malignancies
ePoster Presentation: Thursday, May 5 at 4:00 p.m. PT
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with CAR and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.
SOURCE: Adicet Bio
Post Views: 55
ADI-001 exhibited robust in vitro and in vivo tumor growth inhibition in multiple human lymphoma cell lines, with adaptive and innate mechanisms contributing to its anti-tumor activity
Non-gene-edited ADI-001 gamma delta CAR T cells demonstrated superior resilience to host versus graft targeting when compared to common gene-edited approaches
MENLO PARK, CA & BOSTON, MA, USA I May 05, 2022 I Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced data from a preclinical evaluation of ADI-001 at the International Society for Cell and Gene Therapy (ISCT) Annual Meeting taking place in San Francisco, May 4-7, 2022. ADI-001 is currently being evaluated in an ongoing dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin’s lymphoma (NHL).
The extensive preclinical evaluation reported at ISCT observed that ADI-001 exhibited a predominantly naïve-like T cell memory phenotype, expressed multiple chemokine and innate-activating cell receptors and exhibited robust in vitro and in vivo tumor growth inhibition against multiple human lymphoma cell lines, with adaptive and innate activation pathways contributing to the anti-tumor activity of ADI-001.
Susceptibility to host versus graft targeting was also evaluated using mixed-lymphocyte reactions incorporating up to 13 different allogeneic lymphocyte samples. Non-gene-edited ADI-001 gamma delta CAR T cells demonstrated high levels of endogenous HLA-E expression in the unmodified state and were associated with superior resilience to lymphocyte-mediated clearance when compared to approaches commonly deployed in gene-edited allogeneic cell therapy platforms (β2MKO with or without HLA-E overexpression).
“In this first view comparing Adicet’s non-gene-edited gamma delta CAR T cells to alternative and popularly-reported gene editing strategies, we appreciate the lower preclinical susceptibility to host versus graft targeting demonstrated by non-gene-edited ADI-001,” said Blake Aftab, Ph.D., Chief Scientific Officer at Adicet. “Together, the results of this extended characterization highlight potential advantages of our allogeneic gamma delta T cell platform, with adaptive and innate mechanisms contributing to the anti-tumor activity of ADI-001.”
Poster Presentation Details
Title: Evaluation of non-gene edited allogeneic “off-the-shelf” Vδ1 γδ (gamma delta) CAR T cells targeting CD20 for B cell malignancies
ePoster Presentation: Thursday, May 5 at 4:00 p.m. PT
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with CAR and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.
SOURCE: Adicet Bio
Post Views: 55